Correction to: Cost‑Utility Analysis of Pegaspargase for the Treatment of Acute Lymphoblastic Leukemia in Greece
Clin Drug Investig
.
2023 Feb;43(2):151.
doi: 10.1007/s40261-022-01236-5.
Authors
George Gourzoulidis
1
,
Maria Koulentaki
2
,
Antonis Kattamis
3
,
Maria Bouzani
4
,
Chara Giatra
4
,
Vassiliki Chotzagiannoglou
5
,
Alexandra Beletsi
5
,
Georgia Kourlaba
2
Affiliations
1
ECONCARE LP, Athens, Greece. gourzoulidis.g@gmail.com.
2
ECONCARE LP, Athens, Greece.
3
First Department of Pediatrics, National and Kapodistrian University of Athens, "Aghia Sophia" Children's Hospital, Athens, Greece.
4
Hematology and Lymphoma Department, "Evangelismos" Athens General Hospital, Athens, Greece.
5
Servier Hellas Pharmaceuticals Ltd, Athens, Greece.
PMID:
36580214
DOI:
10.1007/s40261-022-01236-5
No abstract available
Publication types
Published Erratum